Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill for psoriasis tested in everyday clinics

NCT ID NCT07256015

Recruiting now Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 200 Italian patients with moderate-to-severe psoriasis who are already taking deucravacitinib, a daily pill that calms the immune system. Researchers will track how well the drug controls skin symptoms, its side effects, and how it affects quality of life in real-world settings. The goal is to see if the benefits seen in clinical trials hold up outside of controlled research environments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Deucravacitinib (a pill that targets inflammation)
What this could lead to
If successful, this study could confirm that deucravacitinib works well in everyday clinical practice for people with moderate-to-severe psoriasis, offering a convenient oral treatment option.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It only includes patients already on the drug, and long-term safety or effectiveness beyond the study period is not assessed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

follicular lymphoma psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PSORIASIS

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Azienda Ospedaliera Universitaria Integrata Di Verona

    RECRUITING

    Verona, Verona, 37126, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.